Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Insmed (INSM) EBIT (2016 - 2026)

Insmed's EBIT history spans 17 years, with the latest figure at -$153.3 million for Q1 2026.

  • Quarterly EBIT rose 38.21% to -$153.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Mar 2026, down 17.44% year-over-year, with the annual reading at -$1.2 billion for FY2025, 41.96% down from the prior year.
  • EBIT came in at -$153.3 million for Q1 2026, up from -$319.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$88.3 million in Q2 2022 to a low of -$366.0 million in Q3 2025.
  • The 5-year median for EBIT is -$178.3 million (2023), against an average of -$202.7 million.
  • Year-over-year, EBIT plummeted 166.69% in 2023 and then surged 38.21% in 2026.
  • Insmed's EBIT stood at -$151.5 million in 2022, then decreased by 17.69% to -$178.3 million in 2023, then decreased by 29.25% to -$230.4 million in 2024, then tumbled by 38.77% to -$319.7 million in 2025, then skyrocketed by 52.05% to -$153.3 million in 2026.
  • Per Business Quant, the three most recent readings for INSM's EBIT are -$153.3 million (Q1 2026), -$319.7 million (Q4 2025), and -$366.0 million (Q3 2025).